1. Home
  2. KBSX vs ENGN Comparison

KBSX vs ENGN Comparison

Compare KBSX & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FST Corp. Ordinary Shares

KBSX

FST Corp. Ordinary Shares

HOLD

Current Price

$0.95

Market Cap

50.6M

ML Signal

HOLD

Logo enGene Holdings Inc.

ENGN

enGene Holdings Inc.

N/A

Current Price

$1.93

Market Cap

117.2M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
KBSX
ENGN
Founded
1976
1999
Country
Taiwan
Canada
Employees
N/A
N/A
Industry
Recreational Games/Products/Toys
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
50.6M
117.2M
IPO Year
2024
2023

Fundamental Metrics

Financial Performance
Metric
KBSX
ENGN
Price
$0.95
$1.93
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
$21.08
AVG Volume (30 Days)
7.2K
747.1K
Earning Date
05-15-2026
06-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
56.85
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$18.65
N/A
Revenue Next Year
$16.31
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.81
$1.40
52 Week High
$1.77
$12.25

Technical Indicators

Market Signals
Indicator
KBSX
ENGN
Relative Strength Index (RSI) 45.01 57.55
Support Level $0.82 $1.67
Resistance Level $1.03 $1.96
Average True Range (ATR) 0.07 0.08
MACD -0.01 0.01
Stochastic Oscillator 40.00 90.91

Price Performance

Historical Comparison
KBSX
ENGN

About KBSX FST Corp. Ordinary Shares

FST Corp is a renowned manufacturer and innovator in the golf industry with a growing portfolio of creative golf products, including acclaimed golf club shafts and other equipment. The Company has engaged in the research, development, manufacturing, and sales of golf club shafts. The Company currently produces and sells golf club shafts under the Company's own high performance KBS golf club shaft brand, and serves as an original equipment manufacturer (OEM) and original design manufacturer (ODM) for other world-renowned golf equipment brands, golf equipment OEMs, and golf equipment distributors that provide consumers with customized golf club services.

About ENGN enGene Holdings Inc.

enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.

Share on Social Networks: